TMCnet News
ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic CollaborationBOULDER, Colo., July 8, 2019 /PRNewswire/ -- ArcherDX, Inc., a molecular technology company dedicated to developing breakthrough solutions that advance the application of personalized genomic medicine and Ayala Pharmaceuticals, a clinical stage precision oncology company dedicated to developing targeted therapies for genomically defined, clinically underserved cancers, today announced a strategic collaboration to develop companion diagnostic (CDx) tests targeting cancers bearing Notch activating mutations and fusions. "As we continue our work to bring pan-Notch inhibitors to those living with cancers bearing Notch-activating mutations and fusions, we are excited to enter into this collaboration with ArcherDX, a leader in molecular technology," said Roni Mamluk, Ph.D., Chief Executive Officer at Ayala Pharmaceuticals. "We believe that through this partnership we'll have additional tools to identify those patients most likely to respond to the Notch inhibitors that Ayala is developing." "Working closely with biopharma partners to help bring biomarker-driven therapies to individuals diagnosed with cancer is central to our mission to improve access to genomic-based medicine. Partnerships with progressive companies such as Ayala who can leverage our unique ability to provide companion diagnostic solutions from both tissue and blood-based specimens and deploy them at scale as in-vitro diagnostics to laboratories around the world i essential to achieving this mission," said Jason Myers, Co-Founder and Chief Executive Officer of ArcherDX. "We're proud to support Ayala in their pursuit of meaningful new precision oncology treatment options." About ArcherDX ArcherDX is headquartered in Boulder, Colorado. About Ayala Pharmaceuticals Contacts: ArcherDX, Inc: Ayala Pharmaceuticals: View original content to download multimedia:http://www.prnewswire.com/news-releases/archerdx-and-ayala-pharmaceuticals-announce-strategic-companion-diagnostic-collaboration-300880320.html SOURCE ArcherDX |